Your browser doesn't support javascript.
loading
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
Nolan, Terry; Santolaya, Maria Elena; de Looze, Ferdinandus; Marshall, Helen; Richmond, Peter; Henein, Sam; Rheault, Paul; Heaton, Ken; Perrett, Kirsten P; Garfield, Hartley; Gupta, Anil; Ferguson, Murdo; D'Agostino, Diego; Toneatto, Daniela; O'Ryan, Miguel.
Afiliación
  • Nolan T; Vaccine and Immunisation Research Group (VIRGo) at the University of Melbourne School of Population and Global Health and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Santolaya ME; Department of Pediatrics, Hospital Dr Luis Calvo Mackenna, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • de Looze F; School of Medicine, University of Queensland and AusTrials Pty Ltd, Brisbane, Australia.
  • Marshall H; Adelaide Medical School and Robinson Research Institute, The University of Adelaide and Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.
  • Richmond P; Division of Paediatrics and Centre for Child Health Research, University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Princess Margaret Hospital for Children, Perth, Australia.
  • Henein S; University of Toronto, Toronto, Ontario, Canada.
  • Rheault P; Medicor Research Inc, Sudbury, Ontario, Canada.
  • Heaton K; Medicor Research Inc, Sudbury, Ontario, Canada.
  • Perrett KP; Murdoch Children's Research Institute and Melbourne School of Population and Global Health, University of Melbourne and Royal Children's Hospital, Melbourne, VIC, Australia.
  • Garfield H; University of Toronto, Department of Medicine, Queen's University and The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Gupta A; University of Toronto, Department of Medicine, Queen's University and The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Ferguson M; Colchester Research Group, Truro, Nova Scotia, Canada.
  • D'Agostino D; GSK, Amsterdam, the Netherlands.
  • Toneatto D; GSK, Siena, Italy.
  • O'Ryan M; Microbiology and Mycology Program, Institute of Biomedical Sciences, and Millennium Institute of Immunology and Immunotherapy, Faculty of Medicine, Universidad de Chile, Santiago, Chile. Electronic address: moryan@med.uchile.cl.
Vaccine ; 37(9): 1209-1218, 2019 02 21.
Article en En | MEDLINE | ID: mdl-30691980
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunización Secundaria / Vacunas Meningococicas / Inmunogenicidad Vacunal / Infecciones Meningocócicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male País/Región como asunto: America do norte / America do sul / Chile / Oceania Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunización Secundaria / Vacunas Meningococicas / Inmunogenicidad Vacunal / Infecciones Meningocócicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male País/Región como asunto: America do norte / America do sul / Chile / Oceania Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos